Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Daria Shasheleva"'
Autor:
Michael Maschan, Svetlana Radygina, Pavel Trakhtman, Alexei Maschan, Viktoria Zaharova, Dmitriy Balashov, Yulia Olshanskaya, Dmitriy Pershin, Varvara Brilliantova, Agnesa Panferova, Rimma Khismatullina, Galina Novichkova, Alexei Kazachenok, Maria Ilushina, Larisa Shelikhova, Yakov Muzalevskii, Zhanna Shekhovtsova, Daria Shasheleva, Dina Baidildina, Irina Kalinina, Alexander Rumyantsev, Elena Zerkalenkova, Elena Kurnikova
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:e179-e182
We evaluated the outcome of αβ T cell-depleted haploidentical hematopoietic stem cell transplantation (HSCT) in a cohort of children with chemorefractory acute myelogenous leukemia (AML). Twenty-two patients with either primary refractory (n = 10)
Autor:
Maria Ilushina, Elvira Sultanova, Larisa Shelikhova, Svetlana Glushkova, Alexey Kazachenok, Elena Kurnikova, Kristina S. Antonova, Ruslan Nikolaev, Anna Bogoyavlenskaya, Galina Novichkova, Michael Maschan, Dmitriy Balashov, Elena Osipova, Tatiana Salimova, Julia Skvortsova, Yakov Muzalevsky, Alexey Maschan, Daria Shasheleva, Dmitry Pershin, Svetlana Radygina
Publikováno v:
Blood. 138:558-558
Introduction HSCT from matched family donors results in most favorable outcomes among children with severe aplastic anemia (SAA). Despite overall success, morbidity, associated with acute and chronic graft-versus-host disease (GVHD) is not completely
Autor:
Irina Shipitsina, Daria Kobyzeva, Maria Ilushina, Alexander Popov, Julia Abugova, Elena Kurnikova, Ekaterina Mikhailova, Yulia Olshanskaya, Larisa Shelikhova, Maria Fadeeva, Michael Maschan, Dmitriy Balashov, Alexey Maschan, Anna Bogoyavlenskaya, Zhanna Shekhovtsova, Alexey Nechesnyuk, Daria Shasheleva, Rimma Khismatullina, Alexey Kazachenok, Sergey Blagov, Natalia Miakova, Dmitriy Pershin, Yakov Muzalevsky, Galina Novichkova, Dmitry Litvinov
Publikováno v:
Blood. 134:4618-4618
Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) is indicated for patients with relapsed or refractory acute lymphoblastic leukemia. Patients with persistence of minimal residual disease (MRD) before HCT are at increased risk of
Autor:
Alexander Popov, Alexey Kazachenok, Dmitriy Pershin, Alexey Maschan, Daria Shasheleva, Rimma Khismatullina, Larisa Shelikhova, Elena Kurnikova, Evgeny V. Gluhanyuk, Yakov Muzalevsky, Galina Novichkova, Svetlana Kashpor, Irina Kalinina, Dmitriy Balashov, Michael Maschan
Publikováno v:
Blood. 134:150-150
Introduction The outcome HSCT in a cohort of children with chemorefractory acute leukemia (AL) is poor. The incidence of relapse exceeds 50% and survival varies from 10 to 40%. Additional attempts at remission induction with various combinations of c
Autor:
Elena Kurnikova, Irina Shipitsina, Maria Fadeeva, Anna Bogoyavlenskaya, Svetlana Kozlovskaya, Dmitriy Pershin, Michael Maschan, Dmitriy Balashov, Maria Ilushina, Alexey Nechesnyuk, Elena Gutovskaya, Yakov Muzalevsky, Yulia Olshanskaya, Dmitry Litvinov, Zhanna Shekhovtsova, Alexey Maschan, Alexey Kazachenok, Sergey Blagov, Galina Novichkova, Rimma Khismatullina, Natalia Miakova, Irina Kalinina, Daria Shasheleva, Larisa Shelikhova
Publikováno v:
Blood. 132:481-481
Introduction Relapse, graft-versus-host disease (GvHD) and associated non-relapse mortality are the main obstacles to successful hematopoietic stem cell transplantation in children with leukemia. αβ T cell depletion was developed to prevent GvHD an
Autor:
Maria Alyabeva, Larisa Shelikhova, Daria Shasheleva, Rimma Khismatullina, Svetlana Radygina, Anna Bogoyavlenskaya, Sergey Blagov, Olga Molostova, Svetlana Kozlovskaya, Irina Kalinina, Elena Kurnikova, Yakov Muzalevsky, Dmitriy Pershin, Alexander Popov, Olga Illarionova, Yulia Olshanskaya, Natalia Miakova, Dmitry Litvinov, Galina Novichkova, Alexey A. Maschan, Michael Maschan
Publikováno v:
Blood. 132:2084-2084
Introduction The outcome hematopoietic stem cell transplantation (HSCT) in a cohort of children with chemorefractory leukemia is poor. The incidence of relapse exceeds 50% and survival varies from 10 to 40%. Additional attempts at remission induction
Autor:
Michael Maschan, Elena Boyakova, Larisa Shelikhova, Yakov Muzalevsky, Elena Gutovskaya, Irina Shipitsina, Daria Shasheleva, Maria Ilushina, Anna Livshits, Alexei Kazachenok, Julia Skvortsova, Zhanna Shekhovtsova, Alexei Maschan, Rimma Khismatullina, Elana Kurnikova, Dmitriy Balashov
Publikováno v:
Biology of Blood and Marrow Transplantation. 22(3)
Autor:
Elena Boyakova, Larisa Shelikhova, Irina Shipitsina, Rimma Khismatullina, Zhanna Shekhovtsova, Elena Gutovskaya, Andrey Abrosimov, Iakov Muzalevskyi, Michael Maschan, Alexey Maschan, Sergey Blagov, N.V. Myakova, Dmitry Balashov, Galina Novichkova, Daria Shasheleva
Publikováno v:
Blood. 128:4672-4672
Introduction Relapse, graft-versus-host disease (GvHD) and GvHD-associated mortality are major obstacles to success of transplantation from unrelated and haploidentical donors in children with acute lymphoblastic leukemia. Future directions will focu
Autor:
Rimma Khismatullina, Larisa Shelikhova, Julia Starichkova, Alexey Kazachenok, Zhanna Shekhovtsova, Daria Shasheleva, Sergey Blagov, Elena Kurnikova, Dmitry Balashov, Alexey Maschan, Galina Novichkova, Maria Ilyushina, Dmitry Litvinov, Yuliya Skvortsova, Michael Maschan, Iakov Muzalevskyi
Publikováno v:
Blood. 128:3427-3427
Introduction: Graft-versus-host disease (GvHD) remains to be a factor associated with significant morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Bortezomib was shown in vitro to induce selective depletion of
Autor:
Elena Raykina, Michael Maschan, Galina Novichkova, Maria Ilyushina, Svetlana Kozlovskaya, Elena Kurnikova, Daria Shasheleva, Anna Bogoyavlenskaya, Elena Boyakova, Larisa Shelikhova, Alexey Kazachenok, Alexey Maschan, Zhanna Shekhovtsova, Varvara Briliantova, Pavel Trakhtman, Dmitriy Balashov
Publikováno v:
Blood. 128:2294-2294
Introduction Hematopoietic stem cell transplantation from non-sibling donors remains the only curative option for severe aplastic anemia patients refractory to ATG/CsA immunosuppression. Although the results of MUD and haploidentical transplantation